york
april
xinhua
u
s
china
partnership
biotech
sector
promis
benefit
patient
investor
countri
u
s
biotech
firm
investor
ar
mani
veri
smart
scientist
china
thei
ar
veri
entrepreneuri
china
a
big
opportun
biotech
drug
product
rj
tesi
chief
execut
offic
chief
medic
offic
san
diego
base
immunolog
compani
inmun
bio
told
xinhua
interview
tuesdai
ring
nasdaq
stock
market
close
bell
inmun
bio
recogn
veri
earli
investor
capit
china
diversifi
capit
base
north
america
select
univest
secur
a
u
s
base
financi
servic
provid
found
primarili
chines
american
lead
underwrit
a
bid
connect
chines
investor
chines
market
explain
tesi
note
s
a
strategi
ha
paid
s
a
good
invest
opportun
act
lead
placement
agent
inmun
bio
decid
list
nasdaq
conduct
initi
public
offer
guo
yi
chief
oper
offic
univest
secur
cite
high
qualiti
inmun
bio
s
immunotherapi
univest
secur
inmun
bio
chines
citi
includ
beij
shanghai
shenzhen
hong
kong
road
show
arrang
busi
meet
chines
capit
invest
compani
discuss
collabor
opportun
china
s
state
food
drug
administr
sfda
accord
guo
chines
medic
establish
investor
ar
eagerli
search
qualiti
biotech
program
unit
state
chines
medic
institut
cooper
u
s
biotech
compani
licens
technolog
initi
clinic
trial
approv
sfda
ultim
sell
legal
drug
cooper
ha
normal
chines
market
guo
percent
investor
inmun
bio
ar
chines
mainland
guo
ad
univest
secur
ha
a
dream
bring
qualiti
u
s
technolog
china
benefit
chines
peopl
share
price
inmun
bio
surg
dollar
percent
tuesdai
close
u
s
dollar
share
i
fact
share
price
begin
move
a
reflect
peopl
begun
understand
program
understand
hopefulli
reflect
fact
thei
great
prospect
tesi
excit
make
patient
investor
ar
custom
investor
patient
thei
equal
import
ad
inmun
bio
public
nasdaq
stock
market
feb
public
offer
price
dollar
share
compani
aim
rais
million
dollar
fund
research
drug
develop
activ
a
clinic
stage
biotechnolog
compani
focus
reprogram
innat
immun
system
fight
diseas
cancer
neurodegen
diseas
malign
alzheim
s
diseas
